Medical Management of Adult Moyamoya Disease: A Review and Relevant Cases With Ischemic Events
Journal of Stroke · 31.01.2025 · 27 (1) · 1-18
DOI: 10.5853/jos.2024.04273 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Stroke, erschienen am 31.01.2025. Verfasst von Oh Young Bang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 110 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Korean Fund for Regenerative Medicine, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Moyamoya disease (MMD) is a rare and progressive cerebrovascular disorder characterized by stenosis or occlusion of the internal carotid arteries resulting in the development of fragile collateral vessels at the base of the brain. Surgical revascularization is the primary treatment option for preventing ischemic and hemorrhagic events; however, the role of medical management has become increasingly recognized, particularly in cases involving asymptomatic patients or those at a high risk for surgical complications. In this review, we aimed to investigate the current guidelines and evidence supporting various medical management strategies for MMD, including the importance of controlling risk factors and judicious use of antithrombotic therapy. Given the considerable variability in patient presentation, such as age of onset, symptomatology, and comorbid conditions, it is crucial to adopt tailored therapeutic approaches that address each patient’s unique characteristics. The existing literature on medical management is limited. However, individualized strategies may effectively mitigate the risk of ischemic events and improve the overall patient outcomes. Further research is essential to develop comprehensive and standardized treatment protocols for medical management of adult patients with MMD. In addition, ongoing trials and efforts to develop disease-modifying agents are discussed.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- S&E bio Co., Ltd., Seoul, Korea.
- Department of Neurosurgery, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Förderung
- Korean Fund for Regenerative Medicine
- Japan Society for the Promotion of Science
Zitieren
APA
Bang, O. Y., & Fujimura, M. (2025). Medical Management of Adult Moyamoya Disease: A Review and Relevant Cases With Ischemic Events. Journal of Stroke, 27(1), 1-18. https://doi.org/10.5853/jos.2024.04273
Vancouver
Bang OY, Fujimura M. Medical Management of Adult Moyamoya Disease: A Review and Relevant Cases With Ischemic Events. Journal of Stroke. 2025;27(1):1-18. doi:10.5853/jos.2024.04273
BibTeX
@article{Bang2025,
author = {Bang, Oh Young and Fujimura, Miki},
title = {Medical Management of Adult Moyamoya Disease: A Review and Relevant Cases With Ischemic Events},
journal = {Journal of Stroke},
year = {2025},
volume = {27},
number = {1},
pages = {1--18},
doi = {10.5853/jos.2024.04273}
}
EUVIMED